Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > MRKR Marker Therapeutics > Company Executives
MRKR Marker Therapeutics
0.369
-0.005-1.23%
Pre Mkt Price
0.343
-0.0256-6.94%
NamePositionSalaryService DateEducationAgeGenderUpdated
Mr. Peter L. HoangDirector, President and Chief Executive Officer1.62M----50male04/15/2022
Mr. Michael J. LoiaconoChief Accounting Officer, Treasurer and Secretary------56male04/15/2022
Dr. Juan Vera, M.D.Director, Chief Scientific Officer and Chief Operating Officer------42male04/15/2022
Mr. Anthony H. KimChief Financial Officer948.29K----46male09/27/2022
Ms. Mythili KoneruChief Medical Officer901.54K----44female04/15/2022
Ms. Tsvetelina Pencheva Hoang, PhDVice President, Research and Development------49female04/15/2022
Ms. Nadia AgopyanVice President, Regulatory Affairs------60female04/15/2022
Ms. Anna SzymanskaVice President, Quality------48female04/15/2022
Mr. Gerald GarrettVice President, Clinical Operations------57male04/15/2022
Mr. N. David EansorChairman of the Board80.00K----61male05/27/2022
Mr. Steven A. ElmsIndependent Director80.00K----58male04/15/2022
Mr. David Laskow-PooleyIndependent Director80.00K----67male04/15/2022
Mr. John WilsonIndependent Director80.00K----62male04/15/2022
Dr. Katharine Knobil, M.D.Independent Director106.36K----58female04/15/2022
Company Overview More
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company’s MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
CEO: Hoang MBA, Peter L.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top